AMLN/Takeda halt phase-2 obesity trial for safety reasons: http://finance.yahoo.com/news/Amylin-and-Takeda-Voluntarily-prnews-3297796689.html?x=0&.v=1 The trial had been testing the combination of Symlin and metreleptin.